The impact of health technology made simple...

...from the implications of new medical procedures, technologies and policies...

...to measuring their impact on current clinical practices...

...through close collaboration with health care professionals, researchers, and regulators.

Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.

  • Real World Economic Analysis

  • Market Access

  • Horizon Scanning

  • Branding

  • Communications

Contact us to see how Vital Transformation can help you maximise your organisation’s potential.

LATEST RESEARCH

DIA Global 2018: Value Pricing Bootcamp: A Crash Course in How to Use Real World Evidence to Better Measure Outcomes and Evaluate New Innovative Therapies


24th June 2018, Boston, USA



Duane Schulthess, Managing Director of Vital Transformation, and Luca Pani, former Director General of the Italian Medicine's Agency and currently a Faculty Member at the University of Miami, will run a 3 hour and 15 minute Short Course outlining how best to harness RWE to better understand the price, value, and impact of next generation therapies.

LATEST COMMUNICATIONS

Our Communication Services

4 October, 7.30-8.45 CET, Bad Hofgastein

This breakfast session will offer an open debate on the role of IP in EU healthcare innovation, focused on the appropriate role and balance for both public funding and private investments, supported by new research on EU biotech success factors produced by Vital Transformation.

Info & Registration

Find all our communication projects on Better Science, Better Health

MORE RESEARCH

Real world big data for clinical research and drug development

30th December, 2017



The objective of this paper is to identify the extent to which real world data (RWD) is being utilized, or could be utilized, at scale in drug development. Through screening peer-reviewed literature, we have cited specific examples where RWD can be used for biomarker discovery or validation, gaining a new understanding of a disease or disease associations, discovering new markers for patient stratification and targeted therapies, new markers for identifying persons with a disease, and pharmacovigilance.

Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation

21st October, 2015



After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the guidance of the European Medicines Agency in 2014.

Report: The challenges and changes needed to reengineer medicines development in the UK

9th March, 2015



A new report from the ABPI and Vermilion Life Sciences examines the challenges and changes needed for the UK to lead reengineering medicines development, and proposes a new methodology to achieve this.

VITAL HEALTH PODCASTS

SUBSCRIBE

NEWSLETTER

Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…

Sign Up

TWEETS

Our clients include many of the world’s leading health care organisations.

NEWSLETTER SIGN UP

* required
 
GET REAL
EMIF
MIT
PHARMA
EFPIA
Consultancies
MEDIA
VT Health
DGS Outlook
EBE
ADAPT SMART
 

Click here to read our Privacy Statement.